Frontier’s pipeline is focused on delivering precision medicines to patients with cancer.
Frontier’s therapeutic priorities are validated targets with genetically-defined patient populations that have not been successfully drugged using standard screening and chemistry strategies to date. Frontier is challenging the status quo of therapeutic possibilities by applying next generation drug discovery strategies supported by cutting edge technologies. The approach to building our pipeline is to let the science lead the way. This philosophy spans our drug development process – including the identification of targets and the use of genetics to identify patient subtypes most likely to benefit from our therapies, as well as the implementation of biomarker strategies to accelerate development.